BPC-157 Dosing Protocols: What Actually Works (2026 Guide)
The most common BPC-157 dosing error is not choosing the wrong amount. It is running a protocol without knowing the concentration you created during reconstitution, which means every dose you draw is a guess.
Get the maths right and everything else becomes straightforward. Get it wrong and you are injecting an unknown quantity of an expensive peptide into an injury that deserves precision, not approximation.
This guide covers the complete dosing picture: reconstitution, concentration calculations, goal-specific protocols, and the timing and cycle structure that actually produces results.
What Is BPC-157?
BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. It has been studied in animal models for over two decades, with research covering tendon and ligament repair, muscle healing, gut restoration, nerve regeneration, and cardiovascular protection (Sikiric et al., J Physiol Pharmacol, 2018).
Its primary mechanism is angiogenesis (the formation of new blood vessels at injury sites) combined with upregulation of growth factors including VEGF and EGF (Sikiric et al., Curr Med Chem, 2023). These actions create a biochemical environment more permissive to tissue repair than the inflammatory baseline most people accumulate through training or injury history.
It is available in lyophilised (freeze-dried) powder form, typically in 2mg, 5mg, or 10mg vials, which must be reconstituted with bacteriostatic water before use. It is also available in oral capsule form, which is only appropriate for gut-specific applications.
This content is for educational purposes only. These compounds are intended for research use. Nothing here is medical advice.
Reconstitution and Concentration
Before you calculate a dose, you need to know your concentration. Concentration is set at reconstitution and determines every draw volume calculation that follows.
What you need
- BPC-157 vial, lyophilised powder (2mg, 5mg, or 10mg)
- Bacteriostatic water (BAC water), not sterile water, not saline. BAC water contains benzyl alcohol as a preservative, allowing multi-draw use over the life of the vial.
- Insulin syringes, 29–31 gauge, 0.5mL or 1mL (U-100 scale)
- Alcohol swabs, for cleaning vial tops before every needle insertion
Reconstitution method
Swab both vial tops. Draw your target volume of BAC water into the syringe. Angle the peptide vial and add water slowly down the inner glass wall, do not jet it directly onto the powder, which can fragment peptide chains. Swirl gently. Never shake. Inspect the solution (should be clear to faintly yellow). Label the vial with the date and concentration. Refrigerate immediately and use within 30 days.
Concentration reference table
| Vial size | BAC water | Concentration | 250mcg draw | 500mcg draw |
|---|---|---|---|---|
| 2mg (2000mcg) | 2mL | 1000mcg/mL | 25 units (0.25mL) | 50 units (0.5mL) |
| 5mg (5000mcg) | 5mL | 1000mcg/mL | 25 units (0.25mL) | 50 units (0.5mL) |
| 5mg (5000mcg) | 2mL | 2500mcg/mL | 10 units (0.10mL) | 20 units (0.20mL) |
| 10mg (10000mcg) | 10mL | 1000mcg/mL | 25 units (0.25mL) | 50 units (0.5mL) |
The unit reference applies to U-100 insulin syringes, where 1 unit = 0.01mL. The 1000mcg/mL concentration is standard because draw volumes are readable and practical. A 5mg vial with 5mL BAC water is the most common starting configuration.
Dosing by Goal
Dose ranges in BPC-157 research vary based on the target application and body weight, though most human protocol extrapolations cluster within a narrow range. The table below summarises the most common configurations.
| Goal | Dose range | Frequency | Route | Notes |
|---|---|---|---|---|
| Acute musculoskeletal injury | 400–500mcg | Once or twice daily | Subcutaneous | Inject near injury site for targeted effect |
| Tendon/ligament repair | 300–500mcg | Once daily | Subcutaneous | Near-site injection preferred; combine with TB-500 for chronic cases |
| Chronic / multi-site injuries | 250–500mcg | Once daily | Subcutaneous | Neutral site injection; consider Wolverine Stack |
| Gut health (IBS / leaky gut) | 250–500mcg | Once or twice daily | Oral (capsule) | Subcutaneous also effective; oral achieves gut-specific concentration |
| Nerve repair / neuroprotection | 400–500mcg | Once daily | Subcutaneous | Protocol length typically 8 weeks minimum |
| General recovery support | 250mcg | Once daily | Subcutaneous | Lower-dose maintenance use between heavier cycles |
Timing, Cycles, and Duration
When to inject
Most researchers inject BPC-157 in the morning, on an empty stomach or before food. For twice-daily protocols, the second dose is typically early evening. There is no strong evidence that precise timing relative to meals makes a significant difference for subcutaneous administration, but morning injection aligns with circadian patterns of tissue repair and growth factor activity.
Injection site selection
For targeted musculoskeletal injuries, injecting subcutaneously near the injury site concentrates the initial local effect. Common approach: inject within 2–5cm of the injury site (not directly into the joint or tendon). Rotate within the near-site area to prevent localised irritation.
For systemic applications (gut health, general recovery, nerve repair) inject at a neutral site: lower abdomen 2–3 inches from the navel, upper outer thigh, or flank. Rotate sites across the protocol.
Cycle length
Standard cycles are 4–8 weeks. Acute injuries with a clear resolution timeline are typically run as 4-week protocols with assessment at the end before deciding whether to extend. Chronic or complex injuries more commonly require 6–8 weeks. Gut health protocols are typically run for 6–8 weeks to allow meaningful mucosal repair (Sikiric et al., Curr Med Chem, 2023).
After completing a cycle, take an equivalent rest period before running another. Continuous indefinite use is not well-evidenced and is not the recommended approach.
Split dosing vs single dose
Twice-daily dosing (split protocol) is most commonly used for acute or severe injuries where sustained compound presence may be beneficial. For maintenance, general recovery, or less acute applications, once-daily dosing at the same dose is simpler and sufficient. There is no strong evidence that twice-daily dosing provides meaningfully superior outcomes compared to once-daily dosing at equivalent total daily dose in most contexts.
Common Mistakes That Undermine a Protocol
Not knowing the concentration
If you do not know how much BAC water you added, you do not know your concentration. If you do not know your concentration, every dose is an estimate. Do the maths before drawing.
Inconsistent injection timing
Missing doses or inconsistent timing does not catastrophically undermine the protocol, but consistency supports predictable results. Set a fixed time and keep to it.
Expecting acute stimulant-like effects
BPC-157 does not produce an immediate, perceptible effect on the day of injection. Effects build over days and weeks. Early in a protocol, reduced inflammation and improved range of motion are typically the first indicators. Do not abandon a protocol in week one because you cannot feel it working.
Running it alone when a stack is indicated
For chronic tendinopathies or complex multi-site injuries, BPC-157 alone may be insufficient. TB-500 addresses the systemic cellular repair environment that BPC-157's localised signalling cannot cover. If a 4-week BPC-157 cycle has produced limited progress on a long-standing injury, the right next step is often the Wolverine Stack rather than simply repeating the same protocol.
Poor reconstitution technique
Adding water directly onto the powder, shaking instead of swirling, or using sterile water instead of BAC water all compromise the peptide before the first dose. Reconstitution done wrong is money spent on degraded compound.
Always work with a qualified clinician before making changes to your health protocol, particularly when it involves injectable compounds.
The Bottom Line
BPC-157 dosing is not complicated. It is a known compound with well-characterised dose ranges and a predictable arc of effects. Most protocols fall within 250–500mcg per day, run for 4–8 weeks, administered subcutaneously near the target injury or at a neutral site for systemic applications.
The maths matters. Know your concentration, draw the right volume, inject consistently. Everything else follows from that foundation.
Frequently Asked Questions
What is the best dose for a first BPC-157 cycle?
250–300mcg per day is a sensible starting point for a first cycle. It sits within the established research range, allows you to assess your individual response, and can be increased to 400–500mcg in subsequent cycles if needed. There is no benefit to starting at the top of the dose range when you have no prior reference point for how you respond.
How long does one vial of BPC-157 last?
A 5mg vial reconstituted to 1000mcg/mL (5mL BAC water) contains 5000mcg. At 500mcg per day, that is 10 days. At 250mcg per day, it is 20 days. Reconstituted vials should be used within 30 days, so plan your supply around your target dose and cycle length accordingly.
Can I mix BPC-157 and TB-500 in the same syringe?
Yes. There are no documented interaction concerns between BPC-157 and TB-500. On days when both are due, you can draw them into the same insulin syringe and inject at the same site. Reconstitute each in separate vials first, then draw the required volumes of each into one syringe for combined injection.
Do I need to inject near the injury site or can I inject anywhere?
Both approaches work. Near-site injection (within 2–5cm of the target area) concentrates the initial local effect and is preferred for specific, well-defined musculoskeletal injuries. Neutral-site injection (abdomen, thigh, flank) is appropriate for systemic applications, gut health protocols, or multi-site injury patterns. BPC-157 distributes systemically regardless of injection site — near-site injection provides a local concentration advantage, not an exclusive effect.
How do I know if my BPC-157 protocol is working?
Early indicators in the first 1–2 weeks are typically reduced inflammation — less morning stiffness, reduced pain during movement, and improved range of motion in the affected area. Structural tissue improvement becomes more apparent in weeks 3–6. If you reach week 4 of a consistent protocol with no observable change in any of these markers, reassess: protocol design, compound quality, and whether a stack (adding TB-500) would better address the underlying injury pattern.
How long should I rest between BPC-157 cycles?
An off-period equal to the cycle length is the standard guideline. A 4-week cycle warrants a 4-week break; an 8-week cycle warrants an 8-week break. This is a precautionary structure rather than a requirement derived from the research literature, but it is the widely adopted approach in the research community. Continuous indefinite use is not well-evidenced and introduces unknowns around receptor adaptation. Use the rest period to assess outcomes — whether the tissue repair achieved during the cycle has held, and whether a further cycle is actually warranted.
Read Next
Disclaimer: This content is for educational purposes only. These compounds are intended for research use. Nothing here is medical advice. Always work with a qualified clinician before making changes to your health protocol.